- Home
- ESAB vs HALO Comparison
ESAB vs HALO Comparison
Compare ESAB & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- HALO
- Stock Information
- Founded
- ESAB 1904
- HALO 1998
- Country
- ESAB United States
- HALO United States
- Employees
- ESAB N/A
- HALO N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESAB Industrials
- HALO Health Care
- Exchange
- ESAB Nasdaq
- HALO Nasdaq
- Market Cap
- ESAB 6.9B
- HALO 7.4B
- IPO Year
- ESAB N/A
- HALO N/A
- Fundamental
- Price
- ESAB $129.36
- HALO $50.23
- Analyst Decision
- ESAB Buy
- HALO Buy
- Analyst Count
- ESAB 8
- HALO 9
- Target Price
- ESAB $136.13
- HALO $63.78
- AVG Volume (30 Days)
- ESAB 268.9K
- HALO 2.6M
- Earning Date
- ESAB 05-01-2025
- HALO 05-06-2025
- Dividend Yield
- ESAB 0.31%
- HALO N/A
- EPS Growth
- ESAB 16.34
- HALO 55.40
- EPS
- ESAB 4.43
- HALO 3.76
- Revenue
- ESAB $2,729,197,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- ESAB N/A
- HALO $24.79
- Revenue Next Year
- ESAB $5.05
- HALO $22.65
- P/E Ratio
- ESAB $29.31
- HALO $13.36
- Revenue Growth
- ESAB N/A
- HALO 25.64
- 52 Week Low
- ESAB $88.54
- HALO $41.28
- 52 Week High
- ESAB $135.97
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- ESAB 65.71
- HALO 34.42
- Support Level
- ESAB $120.56
- HALO $58.38
- Resistance Level
- ESAB $132.55
- HALO $69.94
- Average True Range (ATR)
- ESAB 3.90
- HALO 3.30
- MACD
- ESAB 1.26
- HALO -0.27
- Stochastic Oscillator
- ESAB 82.47
- HALO 9.30
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.